Literature DB >> 2475958

Flow cytometric analysis of cellular DNA in human prostate cancer: relationship to 5 alpha-reductase activity of the tissue.

F K Habib1, A Bissas, W A Neill, A Busuttil, G D Chisholm.   

Abstract

Flow cytometry of 20 prostate cancer specimens was carried out and the percentage DNA content in each phase of the cell cycle was correlated to the 5 alpha-reductase activity of the tumour. A group of 20 hyperplastic specimens was also entered into this study as control. Tumours were divided into 3 groups on the basis of their 5 alpha-reductase activity. This classification made it possible to identify a group of tumours of which none formed metastases (diploid tumours with 5 alpha-reductase activity greater than 20 pmol/mg protein/30 min and with less than 10% of the cells undergoing mitosis) and a second group of which 78% had metastasised at the time of presentation (diploid tumours with 5 alpha-reductase activity less than 10 pmol/mg protein/30 min and with more than 15% of the cells undergoing mitosis). DNA content within each of the 5 alpha-reductase groups appeared also to correlate with the histological grade of the cancer but no relationship was established with the stage of the disease. Our results suggest that a multi factorial discriminant combining DNA ploidy and 5 alpha-reductase measurements offers a good prognostic index for the assessment of disease progression in prostate cancer and that this might form the basis of a new approach to the treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2475958     DOI: 10.1007/bf00262601

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  12 in total

1.  Prognostic applications of DNA flow cytometry for human solid tumors.

Authors:  O S Frankfurt; S G Arbuck; J L Chin; W R Greco; Z P Pavelic; H K Slocum; A Mittelman; S M Piver; E J Pontes; Y M Rustum
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

2.  The distribution of 5 alpha-reductase and 3 alpha(beta)-hydroxysteroid dehydrogenase activities in the hyperplastic human prostate gland.

Authors:  F K Habib; L Beynon; G D Chisholm; A Busuttil
Journal:  Steroids       Date:  1983-01       Impact factor: 2.668

3.  Nuclear DNA analysis of prostate tissues: correlation with stage and grade of tumour.

Authors:  W A Neill; M Norval; F K Habib
Journal:  Urol Int       Date:  1989       Impact factor: 2.089

4.  Radical perineal prostatectomy for clinical stage B2 carcinoma of the prostate.

Authors:  J S Elder; H J Jewett; P C Walsh
Journal:  J Urol       Date:  1982-04       Impact factor: 7.450

5.  Incidental carcinoma of the prostate: selection for deferred treatment.

Authors:  L L Beynon; A Busuttil; J E Newsam; G D Chisholm
Journal:  Br J Urol       Date:  1983-12

6.  5 Alpha-reductase activity in human prostate cancer is related to the histological differentiation of the tumour.

Authors:  F K Habib; A Busuttil; R A Robinson; G D Chisholm
Journal:  Clin Endocrinol (Oxf)       Date:  1985-10       Impact factor: 3.478

7.  Quantitative and qualitative aspects of flow DNA measurements related to the cytologic grade in prostatic carcinoma.

Authors:  B Tribukait; L Rönström; P L Esposti
Journal:  Anal Quant Cytol       Date:  1983-06

8.  Prostatic carcinoma cell DNA content measured by flow cytometry and its relation to clinical outcome.

Authors:  M V Fordham; A H Burdge; J Matthews; G Williams; T Cooke
Journal:  Br J Surg       Date:  1986-05       Impact factor: 6.939

Review 9.  Prognostic significance of tumor grade and stage in the patient with carcinoma of the prostate.

Authors:  J T Grayhack; D G Assimos
Journal:  Prostate       Date:  1983       Impact factor: 4.104

10.  The application of flow cytometry to the assessment of tumor cell heterogeneity and the grading of human prostatic cancer: preliminary results.

Authors:  M C Benson; P C Walsh
Journal:  J Urol       Date:  1986-06       Impact factor: 7.450

View more
  2 in total

1.  A tribute to professor Geoffrey D Chisholm CBE ChM PPRCS Ed FRCS Eng FRCP Ed FRCPSG FRACS (Hon) FCSSA (Hon) FACS (Hon) FRSE.

Authors:  G Williams
Journal:  J R Soc Med       Date:  1996       Impact factor: 5.344

2.  Current status of 5α-reductase inhibitors in prostate disease management.

Authors:  Dong Il Kang; Jae Il Chung
Journal:  Korean J Urol       Date:  2013-04-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.